Systematic review of MS proteomics/metabolomics in multiple myeloma cohorts
New Blood Test Spots Myeloma Return Months Earlier
This systematic review synthesizes evidence from 19 studies involving 1,077 screened records regarding quantitative mass spectrometry-based …
This new test could give patients and doctors a critical head start in fighting a return of multiple myeloma.
Case Report Describes Non-Secretory Multiple Myeloma With Eosinophilia in a 56-Year-Old Man
Back Pain and High White Cells: A Hidden Cancer Case
This case report details a 56-year-old man presenting with multiple myeloma and eosinophilia.
This case shows how a rare blood cancer can hide behind common symptoms, making early diagnosis difficult but crucial.
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease
Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma.
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Multiple myeloma diagnosis associated with markedly increased hematologic second primary malignancies in 279,894 patients
Multiple myeloma patients show higher risk of second blood cancers, review finds
This systematic review and meta-analysis evaluated second primary malignancy risks in 279,894 patients with multiple myeloma compared to the…
Multiple myeloma patients face a threefold higher risk of developing a second blood cancer compared to the general population, according to …
Systematic review explores necroptosis as a therapeutic target in multiple myeloma
Could a different kind of cell death help treat stubborn blood cancer?
A systematic review integrates current evidence on necroptosis in multiple myeloma.
When standard treatments fail, triggering a different cell death process called necroptosis might kill resistant cancer cells and boost the …
Questions about Multiple Myeloma
Can linvoseltamab improve outcomes for patients with relapsed/refractory multiple myeloma compared to standard care?
Linvoseltamab may improve outcomes for relapsed/refractory multiple myeloma, with a 2025 indirect comparison showing longer survival and higher response rates than teclistamab, a similar bispecific antibody.
Full answer →Does teclistamab cause infections in patients with relapsed/refractory multiple myeloma based on real-world data?
Yes, real-world data shows teclistamab causes infections in about 45% of patients, with severe infections in about 23%, which is lower than clinical trial rates.
Full answer →What is the response rate for talquetamab and teclistamab combination in relapsed/refractory multiple myeloma?
The talquetamab and teclistamab combination shows a 79% overall response rate in relapsed/refractory multiple myeloma with extramedullary disease, based on the phase 2 RedirecTT-1 study.
Full answer →What are the infection rates for patients with relapsed/refractory multiple myeloma taking teclistamab?
In relapsed/refractory multiple myeloma patients taking teclistamab, about 57% experience any infection and about 28% have a severe (grade ≥3) infection, based on a meta-analysis.
Full answer →Do hematologists recommend using tocilizumab with bispecific antibodies for relapsed Multiple Myeloma?
Yes, hematologists recommend using tocilizumab to manage cytokine release syndrome (CRS) caused by bispecific antibodies in relapsed/refractory multiple myeloma, including prophylactic use in outpatient settings.
Full answer →What treatments were used in the case report for ultra-high-risk relapsed Multiple Myeloma?
The case report used a combination of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy after CAR-T cell therapy for ultra-high-risk relapsed multiple myeloma.
Full answer →Can Pomalyst be used to treat Kaposi sarcoma in addition to Multiple Myeloma?
Yes, Pomalyst is FDA-approved for both multiple myeloma and Kaposi sarcoma, including AIDS-related and HIV-negative cases.
Full answer →Is Revlimid approved for maintenance therapy after an autologous stem cell transplant for Multiple Myeloma?
Yes, Revlimid (lenalidomide) is FDA-approved as maintenance therapy after autologous stem cell transplant for multiple myeloma.
Full answer →